Curis (CRIS) Upgraded to “Hold” by Zacks Investment Research
Zacks Investment Research upgraded shares of Curis (NASDAQ:CRIS) from a strong sell rating to a hold rating in a report released on Thursday morning.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
Separately, Guggenheim began coverage on shares of Curis in a report on Monday, October 23rd. They set a buy rating and a $7.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $6.50.
In other Curis news, CEO Ali Ph.D. Fattaey acquired 50,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were acquired at an average cost of $1.06 per share, with a total value of $53,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 115,890 shares in the company, valued at $122,843.40. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.07% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRIS. OxFORD Asset Management LLP purchased a new stake in shares of Curis in the second quarter worth about $115,000. FNY Partners Fund LP lifted its holdings in shares of Curis by 350.0% in the third quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock worth $100,000 after buying an additional 52,500 shares in the last quarter. Voya Investment Management LLC lifted its holdings in shares of Curis by 21.8% in the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after buying an additional 12,207 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Curis by 338.7% in the second quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock worth $158,000 after buying an additional 64,700 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Curis by 8.8% in the second quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock worth $190,000 after buying an additional 8,102 shares in the last quarter. 55.34% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/curis-cris-upgraded-to-hold-by-zacks-investment-research/1859637.html.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.